Previous close | 43.98 |
Open | 44.28 |
Bid | 43.75 x 100 |
Ask | 43.92 x 100 |
Day's range | 43.58 - 45.17 |
52-week range | 14.19 - 72.29 |
Volume | |
Avg. volume | 586,820 |
Market cap | 2.472B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Key Insights Institutions' substantial holdings in Apogee Therapeutics implies that they have significant influence...
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.